208 related articles for article (PubMed ID: 24993672)
1. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
[No Abstract] [Full Text] [Related]
2. Subcutaneous bortezomib: a step towards optimised drug use.
Mateos MV
Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
[No Abstract] [Full Text] [Related]
3. Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.
Kamimura T; Miyamoto T; Yokota N; Takashima S; Chong Y; Ito Y; Akashi K
Eur J Haematol; 2013 Feb; 90(2):157-61. PubMed ID: 23240903
[TBL] [Abstract][Full Text] [Related]
4. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Kamimura T; Miyamoto T; Takashima S; Yokota N; Chong Y; Ito Y; Akashi K
Int J Hematol; 2012 Oct; 96(4):525-7. PubMed ID: 22961216
[No Abstract] [Full Text] [Related]
5. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
6. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Berkowitz A; Walker S
Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
[TBL] [Abstract][Full Text] [Related]
9. New data on subcutaneous bortezomib.
Moreau P; Touzeau C
Acta Haematol; 2015; 133(1):26-8. PubMed ID: 24993571
[No Abstract] [Full Text] [Related]
10. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
He Q; Zhao X; He Y; Tan D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
12. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
[No Abstract] [Full Text] [Related]
15. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
Obeid KM; Ferrara R; Sharma M
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
[No Abstract] [Full Text] [Related]
16. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
[TBL] [Abstract][Full Text] [Related]
17. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Koeppen S
Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
[TBL] [Abstract][Full Text] [Related]
18. Multiple significant bortezomib-related toxicities in one patient: case report and literature review.
Waller JM; Moretto JC; Knopf KB
Clin Lymphoma Myeloma; 2009 Jun; 9(3):E1-4. PubMed ID: 19525183
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
Wilson N; Surati M; Walker BF; Kaufman JL; Harvey RD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):159-61. PubMed ID: 23084405
[No Abstract] [Full Text] [Related]
20. Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma.
Azoulay D; Lavie D; Horowitz N; Suriu C; Gatt ME; Akria L; Perlman R; Braester A; Ben-Yehuda D
Br J Haematol; 2014 Feb; 164(3):454-6. PubMed ID: 24164472
[No Abstract] [Full Text] [Related]
[Next] [New Search]
